Mattia Massimino

Dr. Mattia Massimino

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
MMMattia Massimino
Mattia Massimino
GMGiuseppe Monea
Giuseppe Monea
GMGiuseppe Marinaro
Giuseppe Marinaro
MRMariangela Rubino
Mariangela Rubino
EMElettra Mancuso
Elettra Mancuso
Francesco AndreozziFrancesco Andreozzi
Francesco Andreozzi
Background and Objectives: Among individuals with normal glucose tolerance (NGT), subjects with high levels of plasma glucose (≥155 mg/dL) at sixty minutes during an oral glucose tolerance test (1h-OGTT) are at an increased risk of developing type 2 diabetes. We investigated the association between the triglycerides and glucose (TyG) index, a novel marker of insulin resistance, with 1h-OGTT glucose plasma concentrations. Material and Methods: 1474 non-diabetic Caucasian subjects underwent a 75 g OGTT and were divided into two groups according to the cutoff 1h-OGTT plasma glucose < 155 mg/dL (NGT-1h-low) and ≥ 155 mg/dL (NGT-1h-high). The TyG index was calculated as ln [fasting triglycerides (milligrams per deciliter) × fasting blood glucose (milligrams per deciliter)/2]. Multivariable linear and logistic regression analyses were used to establish the contribution of the TyG index to the variability of 1h-OGTT glucose, and how the former affected the risk of being NGT-1h-high. Results: 1004 individuals were NGT-1h-low and 470 were NGT-1h-high. The TyG index was higher for NGT-1h-high (p = 0.001) individuals, and it was an independent factor influencing 1h-OGTT glycemia (β = 0.191, p < 0.001) after correcting for age, sex, and BMI. The TyG index was the strongest marker associated with the risk of being NGT-1h-high (OR = 1.703, CI 95% 1.34–2.17, p < 0.001) when compared with FPG (OR = 1.054, CI 95% 1.04–1.07, p < 0.001) and the HOMA-IR (OR = 1.156, CI 95% 1.08–1.23, p < 0.001). Conclusions: Our study demonstrated that the TyG index, an efficient and cost-effective marker of insulin resistance, is associated with the variability of early post-challenge glucose levels and is an independent marker of being NGT-1h-high.

10 November 2023 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
ARAlessia Riccio
Alessia Riccio
CCChiara Maria Assunta Cefalo
Chiara Maria Assunta Cefalo
CMCamilla Mazzanti
Camilla Mazzanti
LVLaura Vero
Laura Vero
TFTeresa Vanessa Fiorentino
Teresa Vanessa Fiorentino
GSGiorgio Sesti
Giorgio Sesti
Introduction: This cross‐sectional study aimed to investigate the association between myocardial mechano‐energetic efficiency (MEE) and whole blood viscosity (WBV) in nondiabetic adults participating in the CATAnzaro MEtabolic RIsk factors (CATAMERI) study.Methods: 1143 participants underwent an oral glucose tolerance test and an echocardiogram for myocardial MEE per gram of left ventricular mass (MEEi) measurement. WBV was measured as: [0.12 × h] + [0.17 × (p‐2.07)], where h is haematocrit and p is plasma protein levels.Results: Study population includes 595 males and 548 females with a mean age of 46 ± 12 years and a mean BMI of 30.0 ± 6.2 kg/m2. Individuals with normal glucose tolerance were 63%, while those with impaired fasting glucose, impaired glucose tolerance and or the combination of both were 14.3%, 13% and 9.7%, respectively. A univariate analysis showed that MEEi was significantly associated with sex, age, smoking, BMI, waist circumference, total cholesterol, HDL, triglycerides, fasting glucose, fasting insulin, HOMA‐IR index, glucose tolerance, C‐reactive protein, haematocrit, haemoglobin, plasma protein and WBV. In a multivariable regression model including variables that were significantly associated with MEEi in univariate analysis, MEEi was associated with HOMA‐IR (β = −0.144, p < .001), age (β = −0.140, p < .001), WBV (β = −0.129, p < .001) and glucose tolerance (β = −0.064, p = .04). The independent association between WBV and MEEi remained statistically significant (β = −0.122, p < .001) when antihypertensive therapy and lipid‐lowering therapy were included in the model.Conclusion: WBV is associated with decreased myocardial MEE independently of other cardiovascular risk factors.

24 November 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
FIFrancesco Salvatore Iaquinta
Francesco Salvatore Iaquinta
RGRoberta Grosso
Roberta Grosso
SNStefania Di Napoli
Stefania Di Napoli
VCVelia Cassano
Velia Cassano
SNSaverio Naty
Saverio Naty
Rosa Daniela GrembialeRosa Daniela Grembiale
Rosa Daniela Grembiale
Systemic Sclerosis (SSc) is an autoimmune disorder characterized by organ and tissue fibrosis in which the incidence of atherosclerosis and cardiovascular events is increased, although the exact underlying mechanism remains unclear. Arterial stiffness is a marker of vascular damage that can predict cardiovascular events; therefore, this study aimed to assess the augmentation index (AIx) and pulse wave velocity (PWV), markers of stiffness, in a Systemic Sclerosis population and to detect potentially associated variables. Fourteen female Systemic Sclerosis patients and 14 age- and sex-matched controls were enrolled. Demographic, anthropometric, sero-hematological parameters and disease characteristics were collected for each participant. Arterial stiffness was evaluated using an applanation tonometry system. No differences were found between groups, except for BMI, fasting blood glucose, red blood cells count, hemoglobin, and treatment. Patients had increased augmentation index than the controls (p = 0.008). PWV was significantly decreased in SSc patients compared with the controls (p = 0.007). PWV was correlated with age (r = 0.462; p = 0.048) and BMI (r = 0.458; p = 0.050). Finally, patients with no specific auto-antibody pattern had greater AIx than those expressing anticentromere antibodies. Our study demonstrated that SSc patients had greater AIx, but lower PWV than the controls. In addition, few variables were correlated to arterial stiffness. Further studies are necessary to validate these findings and to establish medication’s role in modifying cardiovascular risk.

12 July 2023 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
ARAlessia Riccio
Alessia Riccio
CMCamilla Mazzanti
Camilla Mazzanti
LVLaura Vero
Laura Vero
TFTeresa Vanessa Fiorentino
Teresa Vanessa Fiorentino
Elena SuccurroElena Succurro
Elena Succurro
GSGiorgio Sesti
Giorgio Sesti

26 November 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MMMattia Massimino
Mattia Massimino
MRMariangela Rubino
Mariangela Rubino
MNMaria Resilde Natale
Maria Resilde Natale
LSLuca Salerno
Luca Salerno
SBStefania Belviso
Stefania Belviso
Francesco AndreozziFrancesco Andreozzi
Francesco Andreozzi
Background: Type 2 diabetes mellitus represents a global health challenge, with chronic hyperglycemia leading to a spectrum of microvascular and macrovascular complications. This narrative review provides a comprehensive and integrated analysis of the nerve growth factor (NGF) axis as a key, yet underrecognized, pathogenic mechanism. Methods: This narrative review was conducted in accordance with scholarly standards for non-systematic syntheses (SANRA). We included both clinical and preclinical studies focusing on NGF/proNGF biology and interventions across major diabetes complications. Discussion: Growing evidence highlights NGF as a pivotal mediator at the crossroads of neuronal, vascular and metabolic pathways. In diabetes, a disrupted balance between mature NGF and its precursor proNGF, favors the detrimental p75NTR pathway, leading to increased cellular stress, inflammation and apoptosis. In this narrative review, we examine how a decline in mature NGF and a relative excess of proNGF contribute to the pathophysiology of diabetic complications across various organ systems. We highlight the dual role of the NGF axis: while NGF-TrkA signaling consistently confers neuroprotective and vasculoprotective benefits, unchecked proNGF-p75NTR activity amplifies tissue damage. Conclusions: Collectively, the evidence identifies NGF as a candidate biomarker for both early tissue distress and therapeutic monitoring. We conclude by outlining key priorities for future research, including the development of standardized assays and the initiation of well-designed clinical trials to translate these promising strategies for early detection and treatment of diabetes-related complications.

13 October 2026 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
ADAntonella Desiderio
Antonella Desiderio
EMElettra Mancuso
Elettra Mancuso
GMGaia Chiara Mannino
Gaia Chiara Mannino
MPMonica Pastorino
Monica Pastorino
CNCecilia Nigro
Cecilia Nigro
FAFrancesco Andreozzi
Francesco Andreozzi